Institution
Hofstra University
Education•Hempstead, New York, United States•
About: Hofstra University is a education organization based out in Hempstead, New York, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 6341 authors who have published 11896 publications receiving 268028 citations.
Topics: Population, Medicine, Health care, Poison control, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The data suggest that the risk for MetS is similarly elevated in the diagnostic subgroups of severe mental illness, and routine screening and multidisciplinary management of medical and behavioral conditions is needed in these patients.
815 citations
••
TL;DR: In this paper, the authors provide an overview of the emerging transport geography of logistics and freight distribution, where transportation is considered as a derived demand with the idea that logistical requirements underline transportation as a component of an integrated demand and the concept of logistical friction is introduced to illustrate the inclusion of the multidimensional notion of impedance in integrated freight transport demand.
800 citations
••
VU University Amsterdam1, Erasmus University Rotterdam2, Karolinska Institutet3, Charité4, Virginia Commonwealth University5, South London and Maudsley NHS Foundation Trust6, QIMR Berghofer Medical Research Institute7, King's College London8, University of Southern Denmark9, University of California, Riverside10, University of Southern California11, University of Minnesota12, University of Queensland13, University College London14, Johns Hopkins University15, University of California, Los Angeles16, University of Crete17, Veterans Health Administration18, Icahn School of Medicine at Mount Sinai19, Harvard University20, Yale University21, Haukeland University Hospital22, Trinity College, Dublin23, University of Edinburgh24, Hofstra University25, North Shore-LIJ Health System26, National Institutes of Health27, Oslo University Hospital28, University of Bergen29, National University of Ireland, Galway30, University of Helsinki31, University of Oslo32, Martin Luther University of Halle-Wittenberg33, Duke University34, Mental Health Research Institute35, National and Kapodistrian University of Athens36, University of Colorado Boulder37, Imperial College London38, University of Manchester39, Wellcome Trust40, Manchester Academic Health Science Centre41, Stanford University42, University of Oregon43, University of Toronto44, University of Michigan45, Erasmus University Medical Center46, Broad Institute47, University of North Carolina at Chapel Hill48
TL;DR: A large-scale genetic association study of intelligence identifies 190 new loci and implicates 939 new genes related to neurogenesis, neuron differentiation and synaptic structure, a major step forward in understanding the neurobiology of cognitive function as well as genetically related neurological and psychiatric disorders.
Abstract: Intelligence is highly heritable1 and a major determinant of human health and well-being2. Recent genome-wide meta-analyses have identified 24 genomic loci linked to variation in intelligence3-7, but much about its genetic underpinnings remains to be discovered. Here, we present a large-scale genetic association study of intelligence (n = 269,867), identifying 205 associated genomic loci (190 new) and 1,016 genes (939 new) via positional mapping, expression quantitative trait locus (eQTL) mapping, chromatin interaction mapping, and gene-based association analysis. We find enrichment of genetic effects in conserved and coding regions and associations with 146 nonsynonymous exonic variants. Associated genes are strongly expressed in the brain, specifically in striatal medium spiny neurons and hippocampal pyramidal neurons. Gene set analyses implicate pathways related to nervous system development and synaptic structure. We confirm previous strong genetic correlations with multiple health-related outcomes, and Mendelian randomization analysis results suggest protective effects of intelligence for Alzheimer's disease and ADHD and bidirectional causation with pleiotropic effects for schizophrenia. These results are a major step forward in understanding the neurobiology of cognitive function as well as genetically related neurological and psychiatric disorders.
800 citations
••
University of Texas MD Anderson Cancer Center1, University of Pittsburgh2, Washington University in St. Louis3, University of Michigan4, University of Southern California5, Memorial Sloan Kettering Cancer Center6, Mayo Clinic7, Duke University8, MedStar Washington Hospital Center9, Fox Chase Cancer Center10, Oregon Health & Science University11, Hofstra University12
TL;DR: The primary endpoint of overall response was not met, but pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and expansion to expanded cohorts of those subtypes is ongoing.
Abstract: Summary Background Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. Methods In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that were members of the Sarcoma Alliance for Research through Collaboration (SARC). Patients with soft-tissue sarcoma had to be aged 18 years or older to enrol; patients with bone sarcoma could enrol if they were aged 12 years or older. Patients had histological evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previous lines of systemic anticancer therapy, had at least one measurable lesion according to the Response Evaluation Criteria In Solid Tumors version 1.1, and had at least one lesion accessible for biopsy. All patients were treated with 200 mg intravenous pembrolizumab every 3 weeks. The primary endpoint was investigator-assessed objective response. Patients who received at least one dose of pembrolizumab were included in the safety analysis and patients who progressed or reached at least one scan assessment were included in the activity analysis. Accrual is ongoing in some disease cohorts. This trial is registered with ClinicalTrials.gov, number NCT02301039. Findings Between March 13, 2015, and Feb 18, 2016, we enrolled 86 patients, 84 of whom received pembrolizumab (42 in each disease cohort) and 80 of whom were evaluable for response (40 in each disease cohort). Median follow-up was 17·8 months (IQR 12·3–19·3). Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including four (40%) of ten patients with undifferentiated pleomorphic sarcoma, two (20%) of ten patients with liposarcoma, and one (10%) of ten patients with synovial sarcoma. No patients with leiomyosarcoma (n=10) had an objective response. Two (5%) of 40 patients with bone sarcoma had an objective response, including one (5%) of 22 patients with osteosarcoma and one (20%) of five patients with chondrosarcoma. None of the 13 patients with Ewing's sarcoma had an objective response. The most frequent grade 3 or worse adverse events were anaemia (six [14%]), decreased lymphocyte count (five [12%]), prolonged activated partial thromboplastin time (four [10%]), and decreased platelet count (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activated partial thromboplastin time in the soft-tissue sarcoma group (three [7%] each). Nine (11%) patients (five [12%] in the bone sarcoma group and four [10%] in the soft-tissue sarcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-related SAEs, including two with adrenal insufficiency, two with pneumonitis, and one with nephritis. Interpretation The primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab. Funding Merck, SARC, Sarcoma Foundation of America, QuadW Foundation, Pittsburgh Cure Sarcoma, and Ewan McGregor.
795 citations
••
University of Manchester1, Imperial College London2, Central Manchester University Hospitals NHS Foundation Trust3, Harvard University4, Ford Motor Company5, King's College London6, University Medical Center Groningen7, University of Cambridge8, University of Oxford9, The Royal Marsden NHS Foundation Trust10, University of Leeds11, University of Michigan12, European Organisation for Research and Treatment of Cancer13, Institute of Cancer Research14, University College London15, United States Military Academy16, VU University Amsterdam17, University of Wisconsin-Madison18, Maastricht University19, Institut Gustave Roussy20, Robarts Research Institute21, Memorial Sloan Kettering Cancer Center22, Newcastle University23, University of Leicester24, Mount Vernon Hospital25, Hofstra University26, Johns Hopkins University27, University of Birmingham28, University of Antwerp29, Duke University30, Brighton and Sussex Medical School31, University of Sheffield32, University of Texas at Austin33
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
Abstract: Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
758 citations
Authors
Showing all 6443 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kevin J. Tracey | 138 | 561 | 82791 |
David B. Allison | 129 | 836 | 69697 |
John M. Kane | 125 | 752 | 60886 |
Peter K. Gregersen | 124 | 451 | 60278 |
Daniel E. Singer | 123 | 445 | 64998 |
Kenneth L. Davis | 113 | 622 | 61120 |
Michael L. Blute | 112 | 527 | 45296 |
David B. Tanner | 110 | 611 | 72025 |
Bertram Pitt | 107 | 754 | 78458 |
John D. Reveille | 102 | 519 | 38105 |
Christoph U. Correll | 100 | 755 | 37523 |
Robert G. Maki | 100 | 416 | 39234 |
Louis R. Kavoussi | 95 | 544 | 31830 |
Howard Leventhal | 89 | 268 | 29144 |
Allan H. Young | 89 | 700 | 47369 |